Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Biol Chem
2012 Mar 16;28712:8852-63. doi: 10.1074/jbc.M111.267757.
Show Gene links
Show Anatomy links
4-(4-(dimethylamino)phenyl)-1-methylpyridinium (APP+) is a fluorescent substrate for the human serotonin transporter.
Solis E, Zdravkovic I, Tomlinson ID, Noskov SY, Rosenthal SJ, De Felice LJ.
???displayArticle.abstract???
Monoamine transporters terminate synaptic neurotransmission and are molecular targets for antidepressants and psychostimulants. Fluorescent reporters can monitor real-time transport and are amenable for high-throughput screening. However, until now, their use has mostly been successful to study the catecholamine transporters but not the serotonin (5HT) transporter. Here, we use fluorescence microscopy, electrophysiology, pharmacology, and molecular modeling to compare fluorescent analogs of 1-methyl-4-phenylpyridinium (MPP(+)) as reporters for the human serotonin transporter (hSERT) in single cells. The fluorescent substrate 4-(4-(dimethylamino)phenyl)-1-methylpyridinium (APP(+)) exhibits superior fluorescence uptake in hSERT-expressing HEK293 cells than other MPP(+) analogs tested. APP(+) uptake is Na(+)- and Cl(-)-dependent, displaced by 5HT, and inhibited by fluoxetine, suggesting APP(+) specifically monitors hSERT activity. ASP(+), which was previously used to study catecholamine transporters, is 10 times less potent than APP(+) at inhibiting 5HT uptake and has minimal hSERT-mediated uptake. Furthermore, in hSERT-expressing oocytes voltage-clamped to -60 mV, APP(+) induced fluoxetine-sensitive hSERT-mediated inward currents, indicating APP(+) is a substrate, whereas ASP(+) induced hSERT-mediated outward currents and counteracted 5HT-induced hSERT currents, indicating ASP(+) possesses activity as an inhibitor. Extra-precise ligand receptor docking of APP(+) and ASP(+) in an hSERT homology model showed both ASP(+) and APP(+) docked favorably within the active region; accordingly, comparable concentrations are required to elicit their opposite electrophysiological responses. We conclude APP(+) is better suited than ASP(+) to study hSERT transport fluorometrically.
Adams,
Flux coupling in the human serotonin transporter.
2002, Pubmed
Adams,
Flux coupling in the human serotonin transporter.
2002,
Pubmed Adams,
Ionic currents in the human serotonin transporter reveal inconsistencies in the alternating access hypothesis.
2003,
Pubmed
,
Xenbase Amara,
Neurotransmitter transporters as molecular targets for addictive drugs.
1998,
Pubmed Andersen,
Location of the antidepressant binding site in the serotonin transporter: importance of Ser-438 in recognition of citalopram and tricyclic antidepressants.
2009,
Pubmed Bancaud,
Molecular crowding affects diffusion and binding of nuclear proteins in heterochromatin and reveals the fractal organization of chromatin.
2009,
Pubmed Barker,
Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter.
1999,
Pubmed
,
Xenbase Barker,
Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter.
1996,
Pubmed Bolan,
D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism.
2007,
Pubmed Bryan-Lluka,
Potencies of haloperidol metabolites as inhibitors of the human noradrenaline, dopamine and serotonin transporters in transfected COS-7 cells.
1999,
Pubmed Buck,
Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium.
1994,
Pubmed Budygin,
Lack of cocaine effect on dopamine clearance in the core and shell of the nucleus accumbens of dopamine transporter knock-out mice.
2002,
Pubmed Busch,
Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1.
1996,
Pubmed
,
Xenbase Celik,
Binding of serotonin to the human serotonin transporter. Molecular modeling and experimental validation.
2008,
Pubmed Chang,
Characterization of a genetically reconstituted high-affinity system for serotonin transport.
1989,
Pubmed Daws,
Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy.
2009,
Pubmed DeFelice,
Pore models for transporters?
1996,
Pubmed Desai,
MPP(+)-induced neurotoxicity in mouse is age-dependent: evidenced by the selective inhibition of complexes of electron transport.
1996,
Pubmed Feighner,
[Clinical effects of serotonin reuptake inhibitors--a review].
1994,
Pubmed Field,
Transmembrane domain 6 of the human serotonin transporter contributes to an aqueously accessible binding pocket for serotonin and the psychostimulant 3,4-methylene dioxymethamphetamine.
2010,
Pubmed Fowler,
A nonradioactive high-throughput/high-content assay for measurement of the human serotonin reuptake transporter function in vitro.
2006,
Pubmed Gether,
Neurotransmitter transporters: molecular function of important drug targets.
2006,
Pubmed Gluck,
Studies on the characterization of the inhibitory mechanism of 4'-alkylated 1-methyl-4-phenylpyridinium and phenylpyridine analogues in mitochondria and electron transport particles.
1994,
Pubmed Gorboulev,
Cloning and characterization of two human polyspecific organic cation transporters.
1997,
Pubmed
,
Xenbase Hahn,
The functional impact of SLC6 transporter genetic variation.
2007,
Pubmed Haunsø,
Pharmacological characterization of a fluorescent uptake assay for the noradrenaline transporter.
2007,
Pubmed Henry,
Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants.
2006,
Pubmed Henry,
Serotonin and cocaine-sensitive inactivation of human serotonin transporters by methanethiosulfonates targeted to transmembrane domain I.
2003,
Pubmed Hilber,
Serotonin-transporter mediated efflux: a pharmacological analysis of amphetamines and non-amphetamines.
2005,
Pubmed Hoffman,
Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system.
1998,
Pubmed Hohage,
Regulation of organic cation transport in IHKE-1 and LLC-PK1 cells. Fluorometric studies with 4-(4-dimethylaminostyryl)-N-methylpyridinium.
1998,
Pubmed Iwamoto,
Na+, Cl-, and pH dependence of the human choline transporter (hCHT) in Xenopus oocytes: the proton inactivation hypothesis of hCHT in synaptic vesicles.
2006,
Pubmed
,
Xenbase Johnson,
Localization of mitochondria in living cells with rhodamine 123.
1980,
Pubmed Johnson,
Monitoring of relative mitochondrial membrane potential in living cells by fluorescence microscopy.
1981,
Pubmed Jørgensen,
Validation of a fluorescence-based high-throughput assay for the measurement of neurotransmitter transporter uptake activity.
2008,
Pubmed Kahlig,
Amphetamine induces dopamine efflux through a dopamine transporter channel.
2005,
Pubmed Keyes,
Coupling of transmembrane proton gradients to platelet serotonin transport.
1982,
Pubmed Krueger,
Reactivation of NADH dehydrogenase (complex I) inhibited by 1-methyl-4-(4'-alkylphenyl)pyridinium analogues: a clue to the nature of the inhibition site.
1993,
Pubmed Li,
Voltage and ionic regulation of human serotonin transporter in Xenopus oocytes.
2006,
Pubmed
,
Xenbase Machaca,
Asymmetrical distribution of Ca-activated Cl channels in Xenopus oocytes.
1998,
Pubmed
,
Xenbase Mager,
Conducting states of a mammalian serotonin transporter.
1994,
Pubmed
,
Xenbase Mason,
Novel fluorescence-based approaches for the study of biogenic amine transporter localization, activity, and regulation.
2005,
Pubmed Mehrens,
The affinity of the organic cation transporter rOCT1 is increased by protein kinase C-dependent phosphorylation.
2000,
Pubmed Murali,
TICT formation in para- and meta-derivatives of N-phenylpyrrole.
2006,
Pubmed Murphy,
Serotonin transporter: gene, genetic disorders, and pharmacogenetics.
2004,
Pubmed Nelson,
The family of Na+/Cl- neurotransmitter transporters.
1998,
Pubmed Petersen,
Ionic interactions in the Drosophila serotonin transporter identify it as a serotonin channel.
1999,
Pubmed
,
Xenbase Ramamoorthy,
Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization.
1993,
Pubmed Ramsey,
Serotonin transporter function and pharmacology are sensitive to expression level: evidence for an endogenous regulatory factor.
2002,
Pubmed
,
Xenbase Richelson,
Synaptic effects of antidepressants.
1996,
Pubmed Rudnick,
Non-neurotoxic amphetamine derivatives release serotonin through serotonin transporters.
1993,
Pubmed Rudnick,
Bioenergetics of neurotransmitter transport.
1998,
Pubmed Rudnick,
Ion-coupled neurotransmitter transport: thermodynamic vs. kinetic determinations of stoichiometry.
1998,
Pubmed Sarker,
The high-affinity binding site for tricyclic antidepressants resides in the outer vestibule of the serotonin transporter.
2010,
Pubmed Schloss,
The serotonin transporter: a primary target for antidepressant drugs.
1998,
Pubmed Schwartz,
Molecular microfluorometry: converting arbitrary fluorescence units into absolute molecular concentrations to study binding kinetics and stoichiometry in transporters.
2006,
Pubmed Schwartz,
Substrate binding stoichiometry and kinetics of the norepinephrine transporter.
2005,
Pubmed Schwartz,
Binding and transport in norepinephrine transporters. Real-time, spatially resolved analysis in single cells using a fluorescent substrate.
2003,
Pubmed Singh,
Antidepressant binding site in a bacterial homologue of neurotransmitter transporters.
2007,
Pubmed Stahl,
Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects.
1998,
Pubmed Talvenheimo,
Mechanism of imipramine inhibition of platelet 5-hydroxytryptamine transport.
1979,
Pubmed Tsuruda,
Influence of ligand binding kinetics on functional inhibition of human recombinant serotonin and norepinephrine transporters.
2010,
Pubmed Vaswani,
Selective serotonin re-uptake inhibitors in anorexia nervosa.
2004,
Pubmed Vaswani,
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review.
2003,
Pubmed Wang,
Electrophysiological effect of fluoxetine on Xenopus oocytes heterologously expressing human serotonin transporter.
2006,
Pubmed
,
Xenbase White,
Serotonin transporters: implications for antidepressant drug development.
2005,
Pubmed Wright,
Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia.
1998,
Pubmed Yamashita,
Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters.
2005,
Pubmed Zapata,
Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors.
2007,
Pubmed Zhou,
Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures.
2009,
Pubmed Zhou,
LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.
2007,
Pubmed
